-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT07115329 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689 ·
Phase: Phase 3 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago, Joliet, Naperville, Skokie
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516 ·
Phase: Phase 3 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Elgin, Orland Park
-
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379 ·
Phase: Phase 3 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407 ·
Phase: Phase 3 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Orland Park
-
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
NCT07716098 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Skokie
-
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176 ·
Phase: Phase 3 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397 ·
Phase: Phase 3 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
NCT06696755 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago, Warrenville
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
NCT04777357 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Chicago, Naperville, Orland Park
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
NCT07276997 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago, Warrenville
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
NCT07610473 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Illinois: Chicago, Skokie
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Naperville
-
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454 ·
Phase: Phase 3 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Evanston
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
NCT06591091 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Cognitive Training as an Adjunct to Ketamine in Real-world Clinics
NCT06526078 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Community-based Approach to Lowering Stress Through Mindfulness
NCT06987799 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss
NCT07073521 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Developing a Digital Intervention for Adolescent Nonsuicidal Self-injury
NCT07224165 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 14 Years to 18 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Digital InteGrated Behavioral treatmeNt for Comorbid obesITy and deprEssion Among Racial and Ethnic Adults Age 50 and Older
NCT06636058 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 50 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
E-Mindfulness Approaches for Living After Breast Cancer
NCT06748222 ·
Phase: Phase 3 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Illinois: Arlington Heights, Aurora, Bloomington, Canton
-
Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression
NCT07610655 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Evaluating the Impact of Focused Muscle Contraction Therapy in U.S. Veterans
NCT05094297 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
NCT05051618 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Experimental Evidence of the Impact of Parental Income on Child Mental Health and Neuroimmune Function
NCT07641244 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 10 Years to 18 Years ·
Sex: All (male and female)
· Illinois: Evanston
-
Fostering Optimal Regulation of Emotion for Prevention of Secondary Trauma (FOREST)
NCT05942469 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Hybrid Type 1 Randomized Pilot Trial of a Peer-led Family and Social Strengthening Group Intervention for Refugee Families
NCT06261463 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 12 Years to 55 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Chicago, Elgin
-
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
My Wellbeing Guide: A Novel Tool for Managing Stress and Improving Quality of Life
NCT05369429 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Chicago
-
Our Voices Matter: Intervention for Depression in Youth
NCT07216326 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 15 Years to 20 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Parents and Babies Pilot
NCT07607613 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Illinois: Chicago
-
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306 ·
Phase: Phase 3 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female)
· Illinois: Chicago, Elgin, Naperville
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
NCT06633016 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Elgin
-
Study of ALTO-300 in MDD
NCT05922878 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Test of Target Engagement of Ambiguity Aversion
NCT06962527 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 25 Years to 60 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Transition Care for FEP
NCT07713849 ·
Phase: Not specified ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Illinois: Chicago, Harvey
-
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
NCT06423430 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 70 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· Illinois: Elgin